Vaccine Reaction Clinical Trial
Official title:
Pursuit of Vaccination in Anaphylactic Reaction to COVID19 Vaccines
Prospective monocentric study designed firstly to estimate the proportion of patients who tolerated the continuation of the COVID-19 2nd injection (absence of anaphylactic manifestations). secondly, to know the proportion of definite anaphylactic reactions in cases of suspected anaphylaxis after the first administration of a COVID-19 vaccine the very complete allergological explorations with both the clinical side, skin tests and biological tests will allow us to highlight the responsibility or not of the components of the vaccine,in particular of the excipients (PEG2000, PS80 and tromethamine) in anaphylactic reactions to COVID-19 vaccines A biological collection will be set up during this clinical study in order to study the immunological mechanisms; the effector cells and the signalling pathways involved in these reactions.
Eligible patients who experience an anaphylactic reaction after the first COVID-19 vaccine injection as part of their routine vaccination will be identified through the hotline set up by our expert center. Three to five weeks after the anaphylactic reaction, the patients will be called for a consultation in the dermatology and allergology department of Tenon hospital for a complete allergological check-up. Then, in the framework of a collegial meeting ,the patient's file will be reviewed in order to specify the history of the allergic disease and the modalities of subsequent COVID-19 vaccination. A follow-up telephonique call at 6months will be made systematically for patients who have received the 2nd dose of vaccine to ensure thatthere are no significant adverse events related to the COVID-19 vaccine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06091410 -
Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines
|
Phase 4 | |
| Completed |
NCT05057910 -
SARS-CoV-2 (Covid-19) RBD Antibody in My Duc Hospital Healthcare Workers
|
||
| Active, not recruiting |
NCT06286488 -
Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza
|
Phase 4 | |
| Recruiting |
NCT05546502 -
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
|
Phase 3 | |
| Completed |
NCT05869201 -
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine
|
Phase 2/Phase 3 | |
| Completed |
NCT04798677 -
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
|
N/A | |
| Recruiting |
NCT05598372 -
Infant Pain During Vaccination and Maternal Anxiety
|
N/A | |
| Recruiting |
NCT06002503 -
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
|
Phase 1 | |
| Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
| Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
| Completed |
NCT03400878 -
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
|
Phase 4 | |
| Completed |
NCT05069714 -
One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.
|
Phase 3 | |
| Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
| Completed |
NCT04576910 -
Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
|
Phase 4 | |
| Not yet recruiting |
NCT05094635 -
Immunogenicity Against SARS-CoV-2 in COVID-19 Close Contacts
|
||
| Recruiting |
NCT05493917 -
A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine
|
||
| Not yet recruiting |
NCT05171946 -
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT05154383 -
Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
|
Phase 4 | |
| Recruiting |
NCT05128721 -
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
|
Phase 1 | |
| Active, not recruiting |
NCT05195151 -
Modification of the COVID-19 Vaccine Response by an Intervention on the Intestinal Flora
|
N/A |